Larimar Therapeutics (LRMR) Receivables - Other (2023 - 2026)

Larimar Therapeutics (LRMR) has reported Receivables - Other for 4 consecutive years, with $267000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other fell 72.84% year-over-year to $267000.0; the trailing twelve-month figure through Jun 2026 stood at $267000.0 (down 72.84% YoY), and the FY2025 full-year result was $747000.0, down 29.13% from the prior year.
• Receivables - Other fell to $267000.0 in Q2 2026 per LRMR's latest filing, from $747000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $1.1 million in Q1 2024 and bottomed at $267000.0 in Q2 2026.
• Historically, Receivables - Other has averaged $821300.0 across 4 years, with a median of $963000.0 in 2024.
• The sharpest annual moves came in 2024 and 2026: Receivables - Other jumped 217.47% in 2024, then sank 72.84% in 2026.
• Over 4 years, Receivables - Other stood at $332000.0 in 2023, then surged by 217.47% to $1.1 million in 2024, then slipped by 29.13% to $747000.0 in 2025, then slumped by 64.26% to $267000.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $267000.0, $747000.0, and $1.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.